Arcutis Biotherapeutics, Inc.
ZORYVE
plaque psoriasis
Resolved
8days ago
FDA decision · Jun 29, 2026
What's at stake
The FDA's approval decision on ZORYVE for plaque psoriasis is due Jun 29, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 15h ago
“Prescription Drug User Fee Act target action date for ZORYVE cream 0.3% for the treatment of plaque psoriasis down to 2 years of age is assigned for June 29, 2026.”